Phase 3 N=48 Voriconazole For Chronic Bronchopulmonary Aspergillosis
Aspergillosis
Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis — 13; 28 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=35 Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: The Primary Outcome Measure Will be the Number of Patients Who Experience a Respiratory Exacerbation Requiring Intravenous Antibiotics in the Two Treatment Groups Over…
Phase 2 N=102 An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
Pulmonary Aspergillosis
Primary: Proportion of Participants Who Completed 12 Weeks of Therapy — 47; 23 Participants
N/A N=249 Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
COVID-19 Respiratory Infection · Aspergillosis
Primary: Incidence of COVID-19 Associated Pulmonary Aspergillosis (CAPA) — 1.69; 0.84; 7.18 Cases per 1000 ICU days
Phase 2 N=32 Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
Invasive Pulmonary Aspergillosis · Lymphoblastic Leukaemia · Myeloblastic Leukaemia
Primary: Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability — 0 participants
Phase 2 N=46 Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
Invasive Aspergillosis
Primary: Safety and Tolerability of Caspofungin in Four Escalating Dosages in Adult Patients With Hematologic Malignancies and Proven or Probable Invasive Aspergillosis — 11; 12…
Phase 3 N=149 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Aspergillosis · Invasive Fungal Infections
Primary: Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT). — 25.0; 50.0; 14.3; 9.1…
Phase 3 N=527 Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
Aspergillosis · Invasive Fungal Infection
Primary: All-cause Mortality Through Day 42 — 18.6; 20.2 percentage of participants
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
Phase 3 N=459 Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
Aspergillosis
Primary: All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive Aspergillosis — 26; 39 participants — p=0.0434
Phase 4 N=88 Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
Aspergillosis; Pulmonary, Invasive (Etiology)
Primary: Number of Participants With IAA-infection at ICU Discharge — 2; 4 Participants
N/A N=116 An Observational Study of Fungal Biomarkers (MK-0000-089)
Aspergillosis
Primary: Average of the Z-scores of the Time-Weighted Averages (TWA) of Fungal Biomarkers Galactomannan (GM) and (1,3)-β-D-glucan (βDG) Over the First Two Weeks of Treatment for…
Phase 2 N=18 Inhaled GM-CSF Therapy of Autoimmune PAP
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Time to Rescue WLL — 18; 30 Months — p=0.0078
Phase 3 N=585 A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
Fungal Infections · Invasive Pulmonary Aspergillosis
Primary: Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population — 15.3; 20.6 Percentage of Participants — p=<.0001
Phase 2 N=2 Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Hereditary Pulmonary Alveolar Proteinosis
Primary: Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test — 17; 33 Percent Change
N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Phase 2 N=138 Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of Treatment — 28.6; 29.3; 32.0 mmHg — p=0.1688
Phase 2 N=62 Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
Allergic Bronchopulmonary Aspergillosis
Primary: Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo — 0.002; 0.203 Liters — p=0.0022
Phase 4 N=45 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Phase 4 N=70 Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
Invasive Fungal Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 55; 9 Participants
Phase 4 N=71 An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections
Pulmonary Fungal Infection
Primary: Number of Participants With Clinical Efficacy — 8; 29; 18; 5 participants
Phase 2 N=15 Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency · Emphysema · Chronic Obstructive Pulmonary Disease
Primary: Pulmonary Microvascular Blood Flow, Mean — 36.9; 35.1 mL blood/minute per 100mL lung — p=0.692
Phase 3 N=725 Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
Phase 2 N=31 A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
Invasive Mucormycosis · Invasive Aspergillosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 29 Participants
Phase 1 N=31 A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events — 1; 0 Participants
Phase 3 N=116 Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)
Aspergillosis
Primary: Number of Participants With an Adverse Event — 15; 6; 57; 27 Participants
Phase 2 N=35 Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Albinism · Inborn Errors of Metabolism · Oculocutaneous Albinism
Primary: Change in Forced Vital Capacity (36 Months) — -23.52; -20.93 % of predicted volume
Phase 4 N=83 Azithromycin in Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans Syndrome · Graft Rejection · Lymphocytic Bronchiolitis
Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants
Phase 2 N=20 Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
Aplastic Anemia · Myelodysplastic Syndromes · Fungal Infection
Primary: the Incidence of Proven/Probable/Possible Fungal Infection — 20 Participants